Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

SirolimUs CoaTed Balloon for The TrEatment of Below The Knee Arterial Disease

FUTURE BTK: Randomized Controlled Trial of First SirolimUs CoaTed Balloon VersUs StandaRd Balloon Angioplasty in The TrEatment of Below The Knee Arterial Disease

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study aims to conduct a randomized, double blind, randomised controlled multicentre trial of sirolimus drug coated balloon versus standard percutaneous transluminal angioplasty for the treatment of below the knee arterial disease.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Age ≥ 21 years or minimum age 2. Rutherford class 4 to 6 in the target limb Intraoperative Inclusion Criteria 3. Single or sequential de novo or re-stenotic lesions (stenosis of \> 50% or occlusions) from 2 to 20cm in the proximal 200mm of below the knee arteries. Lesion is considered as one lesion if there is maximum of 30mm gap between lesions at discretion of investigator. Below the knee arteries are tibioperoneal trunk, anterior tibial artery, posterior tibial artery and peroneal artery 4. Inflow free from flow limiting lesions (\<50% stenosis) confirmed by duplex or angiography. Subjects with flow limiting inflow lesions (\>50% stenosis) can be included if lesion had been treated successfully (\<30% residual stenosis) before or during the index procedure. 5. Target vessel has angiographically documented run off to the foot after treatment (ie. without significant stenosis) Who Should NOT Join This Trial: 1. Comorbid conditions limiting life expectancy ≤ 1 year 2. Subject is currently participating in another investigational drug or device study that has not reached first primary endpoint yet 3. Subject is pregnant or planning to become pregnant during the course of the study 4. Heel gangrene 5. Prior bypass surgery of target vessel 6. Planned amputation of the target limb 7. Previously implanted stent in the target lesion 8. Vulnerable or protected adults 9. Bleeding diathesis or another disorder such as gastrointestinal ulceration which restrict the use of clopidogrel or aspirin 10. Known allergy to sirolimus Intraoperative Exclusion Criteria 11. Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion in the absence of flow limiting dissections or perforations). 12. Target vessel has lesions extending beyond the ankle joint 13. Failure to obtain \<30% residual stenosis in a pre-existing lesion 14. Lesions requiring retrograde access (SAFARI) ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Age ≥ 21 years or minimum age 2. Rutherford class 4 to 6 in the target limb Intraoperative Inclusion Criteria 3. Single or sequential de novo or re-stenotic lesions (stenosis of \> 50% or occlusions) from 2 to 20cm in the proximal 200mm of below the knee arteries. Lesion is considered as one lesion if there is maximum of 30mm gap between lesions at discretion of investigator. Below the knee arteries are tibioperoneal trunk, anterior tibial artery, posterior tibial artery and peroneal artery 4. Inflow free from flow limiting lesions (\<50% stenosis) confirmed by duplex or angiography. Subjects with flow limiting inflow lesions (\>50% stenosis) can be included if lesion had been treated successfully (\<30% residual stenosis) before or during the index procedure. 5. Target vessel has angiographically documented run off to the foot after treatment (ie. without significant stenosis) Exclusion Criteria: 1. Comorbid conditions limiting life expectancy ≤ 1 year 2. Subject is currently participating in another investigational drug or device study that has not reached first primary endpoint yet 3. Subject is pregnant or planning to become pregnant during the course of the study 4. Heel gangrene 5. Prior bypass surgery of target vessel 6. Planned amputation of the target limb 7. Previously implanted stent in the target lesion 8. Vulnerable or protected adults 9. Bleeding diathesis or another disorder such as gastrointestinal ulceration which restrict the use of clopidogrel or aspirin 10. Known allergy to sirolimus Intraoperative Exclusion Criteria 11. Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion in the absence of flow limiting dissections or perforations). 12. Target vessel has lesions extending beyond the ankle joint 13. Failure to obtain \<30% residual stenosis in a pre-existing lesion 14. Lesions requiring retrograde access (SAFARI) 15. Highly calcified lesions (Contiguous calcification on both sides of the lesion) 16. Use of DCBs, drug eluting stent, specialty balloons or artherectomy devices during the index procedure. (Non-compliant balloons are not considered specialty balloons)

Treatments Being Tested

DEVICE

MagicTouch PTA Sirolimus drug coated balloon

For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.

DEVICE

POBA balloon

For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty

Locations (20)

Khoo Teck Puat Hospital
Singapore, Singapore
National University Hospital
Singapore, Singapore
Ng Teng Fong General Hospital
Singapore, Singapore
Sengkang General Hospital
Singapore, Singapore
Singapore General Hospital
Singapore, Singapore
Tan Tock Seng Hospital
Singapore, Singapore
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Kaoshiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
Far Eastern Memorial Hospital
New Taipei City, Taiwan
Taipei Tzuchi Hospital
New Taipei City, Taiwan
China Medical University Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Shin Kong Wu Ho-Su Memorial Hospital
Taipei, Taiwan
Linkou Chang Gung Memorial Hospital
Taoyuan, Taiwan
Phramongkutklao Hospital
Bangkok, Thailand
Rajavithi Hospital
Bangkok, Thailand
Ramathibodi Hospital
Bangkok, Thailand
Siriraj Hospital
Bangkok, Thailand
Vajira Hospital
Bangkok, Thailand
Thammasat University Hospital
Pathum Thani, Thailand